
Novel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III
An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…












